PRL and myeloid sarcoma: As expected, we did not observe significant impact of teriflunomide on PRL number and volume, indicating a huge challenge in the field of MS therapy—targeting the iron-laden microglia at the edge of chronic active lesions, where the chronic active inflammation and axonal injury is compartmentalized behind a virtually closed blood–brain barrier.